CD44

Where the papers sit

16 papers from the last 6 months study CD44 directly · updated from PubMed 12 Oct 2026

• Hyaluronic Acid Nanotherapy

  Hyaluronic acid functionalization is being used to direct nanoparticles toward CD44-rich tumors and inflamed tissues. Charge reversal, glutathione responsiveness and dual stimuli are paired with doxorubicin, podophyllotoxin, paclitaxel, melittin or celecoxib to improve uptake and cytotoxicity. Ferroptosis and immune or macrophage modulation broaden the payload strategy beyond chemotherapy. Evidence remains largely preclinical across cancer, COPD, psoriasis and rheumatoid arthritis.

  9 papers · 56.2%

• CD44 in Triple-Negative Breast Cancer

  Triple-negative breast cancer work is linking CD44 to cancer stemness, inflammatory signaling and metabolic vulnerability. Adapalene is evaluated as a CD44-inhibiting agent, while KYNU blockade suppresses the tryptophan–kynurenine pathway and TNF-α/NFκB–CD44–Akt signaling. Plasma exosome profiling adds a route to characterize breast-cancer subtypes noninvasively. Whether CD44 inhibition can improve durable responses beyond biomarker and pathway effects remains open.

  3 papers · 18.8%

• Others — Immune and Fibrotic Disease

  Gut metabolites, macrophage signaling, cirrhosis immunity and pulmonary fibrosis appear alongside spatial CRISPR genomics. CCL5-mediated hepatocyte–CD44+pDC crosstalk and CHI3L1/PD-1 bispecific targeting point to immune regulation as recurring biology. Primary biliary cholangitis and cirrhosis studies emphasize chemokines and candidate targets, but the cluster has no single disease or therapeutic direction.

  4 papers · 25%